---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-073889"
form_type: "8-K"
ticker: "CLDX"
cik: "0000744218"
company_name: "Celldex Therapeutics, Inc."
filed_at: "2022-06-23T23:59:59+00:00"
generated_at: "2026-06-24T23:47:03.653313+00:00"
event_type: "litigation"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Celldex settles Kolltan merger litigation; replaces up to $172.5M milestones with up to $82.5M in payments

## Summary
- Celldex to pay $15M cash upon signing formal settlement agreement; trial set for June 21, 2022 vacated.
- Additional $15M due upon successful completion of Phase 2 trial of CDX-0159 (barzolvolimab), net of $2.5M credit.
- Additional $52.5M upon first US FDA or EMA regulatory approval of a surviving company product.
- New payments replace prior contingent milestones of up to $172.5M under the 2016 Merger Agreement; broad mutual releases.
- Celldex maintains guidance; cash expected to fund operations through 2025 after paying the $15M initial payment.

## SEC filing metadata
- accession: 0001104659-22-073889
- form_type: 8-K
- ticker: CLDX
- cik: 0000744218
- company_name: Celldex Therapeutics, Inc.
- filed_at: 2022-06-23T23:59:59+00:00
- event_type: litigation
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/744218/000110465922073889/0001104659-22-073889-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/744218/000110465922073889/tm2219126d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-073889
- JSON: https://secwatch.observer/filing/0001104659-22-073889.json
- Plain text: https://secwatch.observer/filing/0001104659-22-073889.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.